EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Biofluid Biomarkers in the Prognosis of Chronic Subdural Hematoma: A Systematic Scoping Review

Georgios Georgountzos iD, Ioannis Gkalonakis, Lykourgos Anastasopoulos, George Stranjalis, Theodosis Kalamatianos

Diagnostics · 22.07.2023 · 13 (14) · 2449

DOI: 10.3390/diagnostics13142449 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Diagnostics, online erschienen am 22.07.2023. Verfasst von Georgios Georgountzos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, General Hospital of Nikaia-Piraeus "Agios Panteleimon", 18454 Athens, Greece. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present systematic scoping review aimed at mapping and analyzing the available literature on biological fluid (biofluid) biomarkers showing promise in the prediction of chronic subdural hematoma (cSDH) recurrence and the prognosis of neurological/functional patient outcome. Twenty-three studies published between 2003 and 2023 investigating a diverse range of biomarkers in hematoma fluid and/or the circulation in 3749 patients were included. Immune cell populations and inflammatory/anti-inflammatory cytokines comprised the most studied category of biomarkers displaying significant findings. A notable time trend in biomarker studies was a recent shift in research focus towards the analysis of circulating biomarkers. Several biomarkers were indicated as independent predictors of cSDH recurrence and/or functional/neurological outcome, including circulating fibrinogen degradation products (FDP), brain natriuretic peptide (BNP-1) and high-density lipoprotein (HDL), as well as blood urea nitrogen (BUN) and the ratios of blood neutrophil to lymphocyte (NLR) or red blood cell distribution width to platelet count (RPR). While studies on cSDH prognostic biomarkers have gained, in recent years, momentum, additional multicenter prospective studies are warranted to confirm and extend their findings. The identification of prognostic biofluid biomarkers in cSDH is an active field of research that may provide future tools, guiding clinical decisions and allowing for the design of treatments based on risk stratification.

Schlagwörter

Stichwörter der Autor:innen

biomarkerchronic subdural hematomaprognosisrecurrence

Autor:innen und Institutionen

  • Department of Neurosurgery, General Hospital of Nikaia-Piraeus "Agios Panteleimon", 18454 Athens, Greece.
  • Clinical and Experimental Neuroscience Research Group, Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, 10676 Athens, Greece.
  • Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, 10676 Athens, Greece.
  • Hellenic Centre for Neurosurgery Research, "Professor Petros S. Kokkalis", 10675 Athens, Greece.

ORCID-Profile: Georgios Georgountzos

Zitieren

APA

Georgountzos, G., Gkalonakis, I., Anastasopoulos, L., Stranjalis, G., & Kalamatianos, T. (2023). Biofluid Biomarkers in the Prognosis of Chronic Subdural Hematoma: A Systematic Scoping Review. Diagnostics, 13(14), 2449. https://doi.org/10.3390/diagnostics13142449

Vancouver

Georgountzos G, Gkalonakis I, Anastasopoulos L, Stranjalis G, Kalamatianos T. Biofluid Biomarkers in the Prognosis of Chronic Subdural Hematoma: A Systematic Scoping Review. Diagnostics. 2023;13(14):2449. doi:10.3390/diagnostics13142449

BibTeX
@article{Georgountzos2023,
  author = {Georgountzos, Georgios and Gkalonakis, Ioannis and Anastasopoulos, Lykourgos and Stranjalis, George and Kalamatianos, Theodosis},
  title = {Biofluid Biomarkers in the Prognosis of Chronic Subdural Hematoma: A Systematic Scoping Review},
  journal = {Diagnostics},
  year = {2023},
  volume = {13},
  number = {14},
  pages = {2449},
  doi = {10.3390/diagnostics13142449}
}
Kostenlos starten →